The IT Neuron Finding That Should Reshape How We Design Rapid-Acting Depression Trials
New Cell data pinpoints intratelencephalic neurons in the anterior insula as the mechanistic key to aiTBS antidepressant effects—here's what...
Leonardo Vando, M.D.
The Alzheimer’s Agitation Approval That Should Rewrite How We Think About Antipsychotics in Geriatric Psychiatry
Auvelity's FDA expansion into Alzheimer's agitation—peak sales now projected at $8B—exposes how long antipsychotics dominated a space where safer...
Semaglutide Just Changed the Math on Alcohol Use Disorder — and Every Addiction Trial Sponsor Should Be Paying Attention
A Lancet RCT shows once-weekly semaglutide cut heavy drinking days in obese AUD patients — targeting a condition where...
The Cognitive Penalty of ECT Has Always Been Its Ceiling — MST Just Removed It
CREST–MST in Lancet Psychiatry shows magnetic seizure therapy matches ECT remission rates with superior cognitive safety—reshaping convulsive therapy trial…
MST Matches ECT Efficacy—and Leaves Memory Intact. The CREST-MST Trial Just Changed the Convulsive Therapy Conversation
The CREST-MST trial in Lancet Psychiatry shows magnetic seizure therapy matches ECT remission rates in TRD with a superior...
France Just Approved What the U.S. Still Won’t Name: IV Ketamine for Acute Suicidal Crisis
France's March 2026 approval of intravenous racemic ketamine for severe suicidal crisis is the first regulatory action of its...
Oral Brexanolone’s Phase 3 Failure Exposes a Gap Ketamine Already Fills
Lipocine's LPCN 1154 just failed its Phase 3 trial for postpartum depression, sending shares down 77%. For psychiatrists treating...
The GLP-1 Mood Signal Is Real — But So Is the Psychiatric Worsening Risk
A pattern I’ve been tracking across my dual-diagnosis patient panel this year: the patients who come in asking about...
The 42% Cost Drop That Should Rewrite How We Design OUD Trials
A pattern I’ve been tracking across my patient panel for the past several months: the patients most likely to...